By Adriano Marchese

 

Bristol Myers Squibb Co. said Monday that two treatments for unresectable or metastatic urothelial carcinoma didn't meet their primary endpoint in a phase 3 trial.

The company said that the Phase 3 CheckMate-901 trial compared Opdivo with Yervoy, also known as nivolumab and ipilimumab, to chemotherapy as a first-line treatment for patients with untreated unresectable or metastatic urothelial carcinoma.

The New York City-based biopharmaceutical company said that the trial didn't meet the primary endpoint.

Bristol Myers Squibb said an independent data monitoring committee recommended that the trial continue to assess other primary and secondary endpoints.

 

Write to Adriano Marchese at adriano.marchese@wsj.com

 

(END) Dow Jones Newswires

May 16, 2022 07:39 ET (11:39 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Bristol Myers Squibb Charts.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Bristol Myers Squibb Charts.